• English
  • Deutsch
  • Log In
    Password Login
    Research Outputs
    Fundings & Projects
    Researchers
    Institutes
    Statistics
Repository logo
Fraunhofer-Gesellschaft
  1. Home
  2. Fraunhofer-Gesellschaft
  3. Artikel
  4. Identification and evaluation of novel synovial tissue biomarkers in rheumatoid arthritis by laser scanning cytometry
 
  • Details
  • Full
Options
2012
Journal Article
Title

Identification and evaluation of novel synovial tissue biomarkers in rheumatoid arthritis by laser scanning cytometry

Abstract
Introduction Suitable biomarkers are essential for therapeutic strategies in personalized medicine in terms of diagnosis as well as of prognosis. With highly specific biomarkers, it is possible, for example, to identify patients with poor prognosis, which enables early intervention and intensive treatment. The aim of this study was to identify and validate biomarkers and possible combinations for a prospective use in immunoscintigraphy, which may improve diagnosis of rheumatoid arthritis (RA) patients with consideration of inflammatory activity in the affected joints. Therefore, we tested several monoclonal antibodies (mAbs) directed against cellular-surface molecules on cells likely to be involved in the pathogenesis of RA. Methods Synovial tissue from patients with long-standing RA (accompanied by synovitis with varying states of current activity) and patients with acute non-RA arthritis were stained for surface molecules on different cell types by using fluorochrome-labeled antibodies. Tissue analysis was done by laser scanning cytometry (LSC), and statistical evaluation, by discriminant analysis and ROC analysis. Results CD11b, HLA-DR, CD90, and CD64 revealed significant differences between tissues from patients with RA and acute non-RA arthritis. Especially with the expression of CD64, both patient cohorts could be discriminated with high sensitivity and specificity. RA classification was improved by simultaneously investigating the expression of two or three different surface proteins, such as HLA-DR, CD90, and CD29 in the tissue. The simultaneous analysis of CD64 together with CD304 or the combination of CD11b and CD38 was suitable for the identification of RA patients with high current activity in synovitis. Conclusions In this study, we showed that LSC is a novel reliable method in biomarker prevalidation in RA. Hence, identified mAbs in situ may allow their potential use in in vivo approaches. Moreover, we proved that biomarker-combination analysis resulted in better discrimination than did single-marker analysis. Combinations of these markers make a novel and reliable panel for the discrimination between RA and acute non-RA arthritis. In addition, further expedient combinations may be novel promising biomarker panels to identify current activity in synovitis in RA.
Author(s)
Füldner, Christiane
Fraunhofer-Institut für Zelltherapie und Immunologie IZI  
Mittag, Anja
Universität Leipzig
Knauer, Jens  
Fraunhofer-Institut für Zelltherapie und Immunologie IZI  
Biskop, Maria
Hepp, Pierre
Universität Leipzig
Scholz, Roger
Universität Leipzig
Wagner, Ulf
Universität Leipzig
Sack, Ulrich
Universität Leipzig
Emmrich, Frank
Fraunhofer-Institut für Zelltherapie und Immunologie IZI  
Tárnok, Attila
Universität Leipzig
Lehmann, Jörg  
Fraunhofer-Institut für Zelltherapie und Immunologie IZI  
Journal
Arthritis Research & Therapy  
Open Access
DOI
10.1186/ar3682
Additional full text version
Landing Page
Language
English
Fraunhofer-Institut für Zelltherapie und Immunologie IZI  
  • Cookie settings
  • Imprint
  • Privacy policy
  • Api
  • Contact
© 2024